An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC)

Trial Profile

An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Pharmacodynamics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 02 Jun 2017 Results of serum metabolomics in nivolumab-treated patients from this and other trial (CA209-038 study) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
    • 11 May 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top